The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.

  title={The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.},
  author={Shirly Amar and Robert H. Belmaker and G Agam},
  journal={Current pharmaceutical design},
  volume={17 22},
Glycogen synthase kinase (GSK-3) is a key enzyme in multiple cell processes. Since many pharmacological compounds that have effects on common metabolic pathways may have uses in many different diseases, we review here the possible involvement of glycogen synthase kinase 3 in diabetes, cancer and CNS diseases. Moreover, diabetes has recently been strongly linked to CNS diseases such as schizophrenia and bipolar illness. GSK-3 is both directly and indirectly inhibited by lithium, a key compound… 

GSK-3 as potential target for therapeutic intervention in cancer

This review will focus on the diverse roles that GSK-3 plays in various human cancers, in particular in solid tumors, and how this pivotal kinase interacts with multiple signaling pathways.

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

Investigation of the interaction between the phosphatidylinositol 3 kinase (PI3K) signaling pathway and the protective effect of novel GPL-1 receptor agonist geniposide on PC12 cells support this theory that GSK3 inhibition can be a promising strategy to ameliorate neurodegenerative developments.

Glycogen Synthase Kinase 3β in Cancer Biology and Treatment

The evidence supporting aberrant GSK3β as a hallmark property of cancer is reviewed and the beneficial effects of G SK3β inhibition on normal cells and tissues during cancer therapy are highlighted.

Glycogen synthase kinase 3β in tumorigenesis and oncotherapy

This review comprehensively summarize the roles of GSK 3β in tumorigenesis and oncotherapy, and focuses on its potentials as an available target in onc therapy.

Phosphoproteomic characterization of glycogen synthase kinase-3

This dissertation represents the first unbiased analysis of GSK-3 phosphorylation substrates in a single cell type and provides the first evidence of Gsk-3 as a general regulator of alternative splicing.

Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice

Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Emerging role of GSK-3 β in the pathobiology of classical Hodgkin Lymphoma Running title : GSK-3 β in classical Hodgkin Lymphoma

The activation of GSK-3β in cHL resulting in inhibition of the Wnt/β-catenin signal cascade and the aberrant accumulation of its activated form in nuclei of Hodgkin Reed-Sternberg and Hodgkin cells is demonstrated.

Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays

This study identified promising fragments, inhibitors of GSK-3β, while proposing an alternative screening workflow that allows facing the flaws that characterize the most common GSK -3β inhibitors through the identification of selective inhibitors and/or inhibitors able to modulate G SK-3 β activity without leading to its complete inhibition.

Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma.